Information Provided By: 
Fly News Breaks for July 30, 2019
GWPH
Jul 30, 2019 | 06:05 EDT
Piper Jaffray analyst Danielle Brill raised her Q2 Epidiolex sales expectations $50.2M from $43M following citing positive Iqvia scripts trends in the quarter. The analyst continues to be encouraged by the Epidiolex launch trajectory and believes sales will beat the Q2 consensus estimate of $45.5M. She keeps an Overweight rating on GW Pharmaceuticals with a $210 price target.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
